ViaCell, Inc.

ViaCell, Inc. processes and stores stem cells from umbilical cord blood and enables the application of human cells as medicine. It offers ViaCord, a service through which families can preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating approximately 40 diseases, including certain blood cancers and genetic diseases. The company also provides ViaCyte to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. In addition, it conducts research and development to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and a technology for expanding populations of these cells. The company’s pipeline is focused in the areas of cancer, cardiac disease, diabetes, and fertility. ViaCell, Inc. was formerly known as T. Breeders, Inc. and changed its name to ViaCell, Inc. in April 2000. The company was founded in 1994 and is based in Cambridge, Massachusetts. ViaCell, Inc. operates as a subsidiary of PerkinElmer Holdings, Inc.